MA50394A - Formulations pharmaceutiques comprenant un agoniste de récepteur d'opioïde en tant que substances actives, leurs procédés de fabrication et leurs utilisations thérapeutiques - Google Patents

Formulations pharmaceutiques comprenant un agoniste de récepteur d'opioïde en tant que substances actives, leurs procédés de fabrication et leurs utilisations thérapeutiques

Info

Publication number
MA50394A
MA50394A MA050394A MA50394A MA50394A MA 50394 A MA50394 A MA 50394A MA 050394 A MA050394 A MA 050394A MA 50394 A MA50394 A MA 50394A MA 50394 A MA50394 A MA 50394A
Authority
MA
Morocco
Prior art keywords
active substances
manufacturing processes
receptor agonist
pharmaceutical formulations
opioid receptor
Prior art date
Application number
MA050394A
Other languages
English (en)
Inventor
Grazia Caivano
Borges Ana Filipa Silva
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA50394A publication Critical patent/MA50394A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA050394A 2017-10-20 2018-10-17 Formulations pharmaceutiques comprenant un agoniste de récepteur d'opioïde en tant que substances actives, leurs procédés de fabrication et leurs utilisations thérapeutiques MA50394A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17197466 2017-10-20

Publications (1)

Publication Number Publication Date
MA50394A true MA50394A (fr) 2021-04-28

Family

ID=60191117

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050394A MA50394A (fr) 2017-10-20 2018-10-17 Formulations pharmaceutiques comprenant un agoniste de récepteur d'opioïde en tant que substances actives, leurs procédés de fabrication et leurs utilisations thérapeutiques

Country Status (10)

Country Link
US (2) US10660849B2 (fr)
EP (1) EP3697381B1 (fr)
JP (1) JP7378391B2 (fr)
KR (1) KR102660711B1 (fr)
CN (1) CN111246841A (fr)
BR (1) BR112020007808A2 (fr)
CA (1) CA3077627A1 (fr)
MA (1) MA50394A (fr)
MX (1) MX2020003697A (fr)
WO (1) WO2019076997A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202106207VA (en) * 2018-12-14 2021-07-29 Pear Therapeutics Inc A digital therapeutic component to optimize induction of buprenorphine-containing products
KR20220003541A (ko) * 2019-04-18 2022-01-10 키에시 파르마슈티시 엣스. 피. 에이. 신생아 오피오이드 금단 증후군 치료를 위한 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8533582A (en) * 1981-07-10 1984-01-12 Reckitt & Colman Products Limited Stable solutions of buprenorphine
US5601077A (en) * 1991-08-07 1997-02-11 Becton, Dickinson And Company Nasal syringe sprayer with removable dose limiting structure
GB9823246D0 (en) * 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
BR0012082A (pt) * 1999-06-16 2002-05-07 Nastech Pharm Co Formulação farmacêutica para administração compreendendo morfina e seu uso
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
PE20070643A1 (es) * 2005-11-21 2007-08-10 Schering Plough Ltd Composiciones farmaceuticas que comprenden buprenorfina
GB2461681A (en) * 2008-04-17 2010-01-13 Pharmasol Ltd Buprenorphine liquid spray formulation with solvent and antioxidant
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
ES2887104T3 (es) * 2011-09-19 2021-12-21 Orexo Ab Comprimidos sublinguales resistentes al abuso que comprenden buprenorfina y naloxona
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
US9034401B1 (en) * 2014-01-23 2015-05-19 Matrixx Initiatives, Inc. Pharmaceutical compositions comprising plant extracts and methods for reducing duration of a common cold using same
US20160175296A1 (en) * 2014-12-23 2016-06-23 Arx, Llc Method of producing uniform buprenorphine-containing formulations

Also Published As

Publication number Publication date
MX2020003697A (es) 2020-08-13
RU2020115819A (ru) 2021-11-23
KR102660711B1 (ko) 2024-04-26
CN111246841A (zh) 2020-06-05
US20190117556A1 (en) 2019-04-25
EP3697381B1 (fr) 2023-06-07
US20200237650A1 (en) 2020-07-30
WO2019076997A1 (fr) 2019-04-25
RU2020115819A3 (fr) 2021-11-23
BR112020007808A2 (pt) 2020-10-20
EP3697381C0 (fr) 2023-06-07
KR20200073223A (ko) 2020-06-23
EP3697381A1 (fr) 2020-08-26
JP2020537682A (ja) 2020-12-24
US10660849B2 (en) 2020-05-26
JP7378391B2 (ja) 2023-11-13
CA3077627A1 (fr) 2019-04-25

Similar Documents

Publication Publication Date Title
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
FR2949062B1 (fr) Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
ECSP17084331A (es) Formulaciones farmacéuticas
WO2017191130A3 (fr) Inhibiteurs d'arginase et leurs applications thérapeutiques
MA46867A (fr) Formulations pharmaceutiques
MA50189A (fr) Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CL2008002479A1 (es) Composicion farmaceutica que comprende: a) una o mas sustancias medicamentosas, b) un lipido, c) un co-lipido y d) un mejorador de flujo; formulacion en polvo seco; procesos de elaboracion.
UY36761A (es) Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma
MA49977A (fr) Combinaisons pharmaceutiques comprenant un anticorps anti-ly75
MA52174A (fr) Anticorps dirigés contre le récepteur 1 des chimiokines et leurs utilisations thérapeutiques
MA55015A (fr) Formulations pharmaceutiques
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
MA50394A (fr) Formulations pharmaceutiques comprenant un agoniste de récepteur d'opioïde en tant que substances actives, leurs procédés de fabrication et leurs utilisations thérapeutiques
MA41326A (fr) Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation
FR2984750B1 (fr) Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
MA50670A (fr) Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose
EP3539978A4 (fr) Fragment de nkx3.2 et composition pharmaceutique le comprenant en tant que principe actif
MA49947A (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
MA42611A (fr) Traitement combiné comprenant l'administration de 2-amino-3,5,5-trifluoro-3,4,5,6-tétrahydropyridines
MA45718A (fr) Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1, utilisations et compositions pharmaceutiques associées
MA54095A (fr) Formulations pharmaceutiques aqueuses
MA44859A (fr) Pseudodimères d'oxazoline, compositions pharmaceutiques et utilisation correspondantes
MA53812A (fr) Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
MA51826A (fr) Compositions pharmaceutiques comprenant de la teixobactine